Vertex (VRTX) PT Raised to $210 at Baird

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. LITE
4. AAPL
5. ABBV
6. MRVL
7. CL
8. LYB
9. TFII
10. NVT

Go back to Vertex (VRTX) PT Raised to $210 at Baird

FDA Approves TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation

October 21, 2019 3:55 PM EDT

- For the first time, approximately 6,000 patients with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease

-12,000 people with one or two F508del mutations who are currently eligible for one of Vertexs three other FDA-approved cystic fibrosis medicines are now also eligible for TRIKAFTA-

-Approval is based on two positive global Phase 3 studies in people with cystic fibrosis ages 12 and older with one F508del mutation and one minimal function mutation and in people with two F508del... More